http://www.cnr.it/ontology/cnr/individuo/prodotto/ID202703

Thyroid hormone, amiodarone therapy, and prognosis in left ventricular systolic dysfunction (Articolo in rivista)

Type

Prodotto della ricerca (Classe)
Articolo in rivista (Classe)

Label

Thyroid hormone, amiodarone therapy, and prognosis in left ventricular systolic dysfunction (Articolo in rivista) (literal)

Anno

2011-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

10.3275/7351 (literal)

Alternative label

Coceani, M. [ 1 ]; Molinaro, S. [ 2 ]; Scalese, M. [ 2 ]; Landi, P. [ 2 ]; Carpeggiani, C. [ 2 ]; L'Abbate, A.[ 3 ]; Iervasi, G. [ 2 ]; Pingitore, A. [ 2 ] (2011)
Thyroid hormone, amiodarone therapy, and prognosis in left ventricular systolic dysfunction
in Journal of endocrinological investigation (Testo stamp.)
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Coceani, M. [ 1 ]; Molinaro, S. [ 2 ]; Scalese, M. [ 2 ]; Landi, P. [ 2 ]; Carpeggiani, C. [ 2 ]; L'Abbate, A.[ 3 ]; Iervasi, G. [ 2 ]; Pingitore, A. [ 2 ] (literal)

Pagina inizio

e144 (literal)

Pagina fine

e148 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni

ID_PUMA: cnr.ifc/2011-A0-162 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

34 (literal)

Rivista

Journal of endocrinological investigation (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

6 (literal)

Note

ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

[ 1 ] Fdn G Monasterio CNR Reg Toscana, Pisa, Italy; [ 2 ] CNR Inst Clin Physiol, Pisa, Italy; [ 3 ] Scuola Super Sant Anna, Pisa, Italy (literal)

Titolo

Thyroid hormone, amiodarone therapy, and prognosis in left ventricular systolic dysfunction (literal)

Abstract

BACKGROUND: Amiodarone protects patients with left ventricular systolic dysfunction (LVSD) against serious arrhythmias, but it also has numerous side effects on non-cardiac organs, such as the thyroid. Indeed, amiodarone may inhibit the peripheral conversion of T4 into T3. Pathologically reduced serum levels of T3 - the so-called \"low T3 syndrome\" (LOWT3) - increase mortality in patients with LVSD and not on amiodarone. AIM: The aim of the study was to examine the relationship between thyroid hormone status, amiodarone therapy, and outcome in a population with LVSD. MATERIAL/SUBJECTS AND METHODS: A total of 2344 patients with LVSD and free of overt hyper-and hypothyroidism were enrolled. The population was divided into 4 groups: group 1 (LOWT3 and amiodarone therapy, no.=126), group 2 (isolated amiodarone therapy, no.=74), group 3 (isolated LOWT3, no.=682), group 4 (controls, no.=1462). RESULTS: Kaplan-Meier curves showed, after a mean follow-up of 31 months, increased total and cardiac mortality in groups 1 (30% and 20%, respectively), 2 (23%, 11%), and 3 (22%, 12%) compared to group 4 (total mortality log-rank 82.8, p<0.0001; cardiac mortality log-rank 63.1, p<0.0001). At Cox analysis, adjusted for several clinical variables, survival was reduced in groups 1 and 3 compared to group 4. Group 2 had a similar mortality to group 4, although the number of patients was too limited to accurately assess the effect of amiodarone on long-term prognosis. CONCLUSIONS: LOWT3 exerts an adverse impact on prognosis in LVSD, which is not influenced by concomitant amiodarone therapy. (literal)

Prodotto di